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AbstrAct
background: The aim of this study was to evaluate the effectiveness of prophylactic corticosteroids to prevent pain flare (pF) 
in bone metastases treated with radiotherapy performing a meta-analysis of randomized clinical trials (rcT).
Materials and methods: rcTs were identified on Medline, embase, the cochrane Library, and the proceedings of annual 
meetings through June 2020. We followed the prIsMa and MOOse guidelines. a meta-analysis was performed to assess if 
corticosteroids reduce the pF, pain progression, and the mean of days with pF compared with the placebo. a p-value < 0.05 
was considered significant.
results: Three rcTs with a total of 713 patients treated were included. The corticosteroids reduced the occurrence of early 
pF 20.5% (51/248) versus 32% (80/250) placebo, Or = 0.55 (95% cI: 0.36–0.82, p = 0.002). The mean days of pF were reduced 
to 1.6 days (95% cI: 1.3–1.9, p = 0.0001). prophylactic corticosteroids had more patients with no pF and no pain progression, 
Or = 1.63 (95% cI: 1.14–2.32, p = 0.007). No significant corticosteroids effect was observed for pain progression (p = ns) and 
late pF occurrence (p = ns).  
conclusion: prophylactic corticosteroids reduced the incidence of early pF, the days with pF, resulting in a superior rate of pa-
tients with no pF and no pain progression, but with no significant benefit for reducing pain progression or late pF occurrence. 
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Bone pain due to metastases is the most com-
mon symptom demanding treatment in oncological 
patients [1]. Beside the pain, bone metastases (BM) 
can cause spinal cord compression, pathological 
fractures, and hypercalcemia [2]. All these compli-
cations secondary to BM have a massive impact on 
the quality of life (QoL). 
Radiotherapy (RT) has a long history in the treat-
ment of bone pain due to BM [2]. Several random-
ized clinical trials and meta-analyses show a sig-
nificant reduction in pain and metastasis-related 
bone events with RT administration [3]. However, 
after the onset of an RT course, some patients may 
develop a transitory worsening of bone pain [4]. 
This effect is denominated as PF. The estimated 
incidence rate of PF is around 40% [5]. In general, 
the effect occurs within the first 5 days after day one 
of RT administration (88%) and, frequently, it has 
a mean duration of 3 days [6, 7]. The radiobiologic 
mechanism that explains the occurrence of PF after 
RT is associated with the cytotoxic effect in the 
tissue irradiated [8, 9]. RT produces and triggers 
an inflammatory response in the bone target ir-
radiated. The inflammatory response induced by 
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RT increases pro-inflammatory cytokines and che-
mokines in the local tissue, which worsens bone 
pain transitionally [9]. The relationship between 
RT and inflammatory response in the bone tissue 
has actively supported the design of randomized 
clinical trials evaluating glucocorticoids to prevent 
PF after RT [5, 10, 11]. Recently, some randomized 
clinical trials have been published, demonstrating 
contradictory results about corticosteroids’ efficacy 
in reducing the incidence of PF [12–14]. The dif-
ferences in the sample size, corticosteroids dose, 
and treatment duration are considered some of the 
problems of the studies analyzed individually.
Meta-analysis is a valuable tool to solve medical 
literature problems, mainly related to sample size 
and insufficient power of studies to find statistical 
differences between the arms of randomized clini-
cal trials [15].
Based on this scenario, we designed a meta-anal-
ysis of randomized clinical trials to provide a gener-
al overview of the outcomes of the prophylactic use 
of corticosteroids to prevent PF in bone metastases 
irradiated.
Materials and methods
We conducted a systematic review and me-
ta-analysis according to the Preferred Reporting 
Items for Systematic Reviews and Meta-analysis 
(PRISMA) statement [16]. Two reviewers per-
formed the research, selecting articles initially by 
title and abstract, and then read the full article.
A systematic search was conducted by two of 
the investigators in PubMed, the Cochrane Cen-
tral Register of Controlled Trials, and Embase for 
studies assessing the treatment outcomes of pro-
phylactic corticosteroids to prevent PF in painful 
bone metastases treated with radiotherapy: (“bone 
and bones” [MeSH Terms] OR (“bone” [All Fields] 
AND “bones” [All Fields])) OR “bone and bones” 
[All Fields]) OR “bone” [All Fields]) AND (“metas-
tase” [All Fields]) OR “metastasis” [All Fields]) OR 
“neoplasm metastasis” [MeSH Terms]) OR (“neo-
plasm” [All Fields] AND “metastasis” [All Fields])) 
OR “neoplasm metastasis” [All Fields]) OR “metas-
tases” [All Fields]) OR “metastasize” [All Fields]) 
OR “metastasized” [All Fields]) AND (“radiothera-
py” [MeSH Terms] OR “radiotherapy” [All Fields]) 
OR “radiotherapies” [All Fields]) OR “radiothera-
py” [MeSH Subheading]) OR “radiotherapy s” [All 
Fields]) AND (“pain” [MeSH Terms] OR “pain” 
[All Fields]) AND (“flare” [All Fields] OR “flares” 
[All Fields]). The lists containing the articles and 
reviews were checked, and possible related articles 
were tracked to complement the electronic query. 
Searches were performed from January 2000 up to 
June 2020 and were limited to publications in any 
language.
study selection
We included only randomized clinical trials that 
evaluated the treatment outcomes of prophylactic 
corticosteroids to prevent PF compared with pla-
cebo in painful bone metastases treated by radio-
therapy. Retrospective, non-randomized prospec-
tive studies and case reports were excluded.
patients
We included studies of patients with painful 
bone metastases from any histological subtype, 
submitted or not to previous treatment with the 
metastatic lesion located in any bone treated by RT, 
and who received corticosteroids as a preventive 
treatment of the PF. 
Intervention
We evaluated the efficacy of corticosteroids as an 
intervention to prevent PF. Studies administrating 
oral or intravenous corticosteroids before and dur-
ing the radiotherapy course were included. Stud-
ies using multiple or single radiotherapy schedules 
with any total dose were included. Studies using 
conformational radiotherapy, tomotherapy, intensi-
ty-modulated radiotherapy, or VMAT, or stereotac-
tic body radiotherapy (SBRT) were allowed.
Outcomes
The primary endpoint of the meta-analysis was 
the incidence of PF. PF was considered a minimum 
of a two-point increase in the worst pain score for 
the treated site without reducing analgesic intake, 
or > 25% increase in analgesic intake based on daily 
oral morphine equivalence without reducing the 
worst pain score. We considered PF to be early 
when the event occurred between days 0–5, or late 
when it started on 6–14 days. Pain progression was 
defined as either an increase in the worst pain score 
of two or more without analgesic decrease or an 
analgesic increase of 25% or more from baseline 
without reducing the worst pain score.
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clinical data
Two reviewers independently selected data using 
a standardized method. The following information 
was collected: author, year, study design, number 
of patients, gender, bone location, histological sub-
type, RT dose and RT technique, dexamethasone 
dosage, PF rate, pain progression rate, and days 
of PF. Two reviewers were in charge of gathering 
all data for all studies using a standardized data 
extraction form. A third reviewer was used to solve 
different issues by consensus.
Data synthesis and analysis
The rates of events of each outcome were calcu-
lated using the Odds ratio with the 95% confidence 
interval. The comparison for continuous variables 
was performed by mean difference estimation. 
The I2 statistic illustrates the percentage of di-
vergence across studies that is due to heterogeneity 
rather than chance. An I2 value lower than 25% 
was interpreted as a low level of heterogeneity. We 
used the random-effect model due to a relevant 
variation in studies’ characteristics. Two distinct 
methods were used to examine and explain the 
diversity among different studies results: subgroup 
analyses and meta-regression. A p-value lower than 
0.05 was considered significant in all analyses. The 
meta-analysis was performed using the Open Me-
ta-Analyst free open software.
results
We identified in our searches 1,980 studies re-
porting the occurrence of PF after RT in painful 
bone metastases. After applying the inclusion cri-
teria, 1,964 studies were excluded. The published 
studies were excluded due to many reasons, as 
described in the flowchart in Figure 1. Therefore, 
we selected 3 studies, including 713 patients using 
prophylactic dexamethasone to prevent PF after RT 
in painful BM compared with placebo. All studies 
were RCTs, and all of them were published from 
2014 to 2020. In general, the treatment groups were 
similar for age, sex, and histological type. The main 
difference between the RCTs was due to the tumor 
location included in the Youssef et al. In this study, 
the authors only included patients with spine me-
tastases randomized to receive methylprednisolone 
or placebo (saline infusion). Table 1 summarizes 
the characteristics of the studies included in the 
present meta-analysis. The placebo was the control 
arm in the other two trials, with dexamethasone 
8 mg/4–5 days as a similar intervention arm. In 
Youssef et al., the intervention arm was intravenous 
methylprednisolone (5 mg/kg) the day before RT.
early pF rate
Two studies with 498 patients reported early PF 
as an outcome. Pooling the early PF rates of stud-
ies, comparing dexamethasone versus placebo, the 
rate of early PF was 20.5% (51/248) versus 32% 
(80/250) placebo, resulting in an OR = 0.55 (95% 
CI: 0.36–0.82, p = 0.002), with no heterogeneity, 
I2 = 0% (Fig. 2A).
Late pF
Three RCTs with 611 patients reported late 
PF rate as an outcome. Pooling the late PF rate 
of RCTs, comparing dexamethasone versus place-
bo, the rate of late PF was 18.6% (56/301) versus 
21.6% (67/310), providing an OR = 0.74 (95% CI: 
0.41–1.33), with no heterogeneity, I2 = 0% (Fig. 2B).
Mean days with pF
Three studies, including 611 patients, reported 
the mean days with PF. Combining the studies 
and calculating the mean difference between cor-
ticosteroids and placebo arms, a significant differ-
ence was found of 1.94 days (95% CI: –1.3 to –2.5, 
p < 0.0001), with heterogeneity I2 = 78%, p = 0.001) 
(Fig. 3A). In the sensitivity analysis, we removed the 
Youssef study by exploring the heterogeneity due to 
the inclusion of only spinal metastases. After that, 
the two studies combined gave a mean difference in 
PF days of –1.6 (95% CI –1.3 to –1.9, p = 0.0001), 
with no heterogeneity, I2 = 16%, p = 0.27, validating 
the outcome (Fig. 3B).
No pF/no pain progression
Two studies with 498 patients reported no PF/PP 
as an outcome. Pooling the no PF/PP of studies, 
comparing dexamethasone versus placebo, the 
rate of no PF/PP was 52% (129/248) versus 40% 
(100/250) placebo, resulting in an OR = 1.63 (95% 
CI: 1.14–2.32, p = 0.007), (Fig. 2), with no hetero-
geneity, I2 = 0% (Fig. 4A).
pain progression
Two studies reported PP as an outcome. Two 
studies with 498 patients reported PP as an out-












































Full-text articles excluded, 
with reasons 
(n = 13)




Figure 1. Flowchart of studies included in the meta-analysis
table 1. characteristics of the studies included in the meta-analysis
Study Chow et al. [14] Liden et al. [12] Youssef et al. [13]
Variables Corticosteroid Placebo Corticosteroid Placebo Corticosteroid Placebo
patients 148 150 100 100 60 60
age (mean) 67 68 65 63










































corticosteroid Dexamethasone Dexamethasone Methylprednisolone
corticosteroid dosage
8 mg/day  
for 5 days
8 mg/day  
for 4 days
5 mg/kg 1 days 
before rT
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Figure 4. A. No pain flare and no pain progression; b. pain progression
Figure 2. A. early pain flare; b. Late pain flare
Figure 3. A. Mean of days with pain flare without sensitivity analysis; b. Mean of days with pain flare with sensitivity analysis
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come. Pooling the PP of studies, comparing dexa-
methasone versus placebo, the rate of PP was 11.2% 
(28/248) versus 13.6% (34/250) placebo, resulting 
in an OR = 0.81 (95% CI: 0.4–1.3, p = NS) (Fig. 4B), 
with no heterogeneity, I2 = 0%.
Discussion
The present study is the first meta-analysis, in-
cluding only randomized clinical trials, assessing 
the benefit of prophylactic corticosteroids admin-
istration to prevent PF in painful BM. We gathered 
a total of 3 RCTs to estimate the incidence of PF, 
PP, and days of PF, comparing corticosteroids with 
placebo. In general, the heterogeneity for most of 
the outcomes evaluated was not significant, which 
validated our findings. We divided the analysis of 
PF into early and late, mainly to investigate if the 
corticosteroids effect is durable or transitory. The 
meta-analysis shows a significant effect of cortico-
steroid for PF occurrence in the first week of the ini-
tiation of radiotherapy. On the other hand, prophy-
lactic treatment had no significant difference com-
pared with the placebo for the late occurrence of PF. 
This finding raises the question if corticosteroids 
dosage or the short intake time (4–5 days) is inef-
fective in producing a long-lasting protective effect 
for the occurrence of PF. In both RCTs using oral 
dexamethasone, a dose of 8 mg/day for 4–5 days was 
used. The RCT conducted by Liden et al. had three 
arms with one of them using 8mg for 1 day followed 
by 3 days of placebo. The early PF rate in this arm 
was 73%, with no significant difference for 8 mg per 
4–5 days (52%) in the early evaluation. Although 
our study was not designed to evaluate the length 
of corticosteroids administration, these data make 
this question inevitable. The literature reports that 
the majority of PF occurs during the first week of 
RT [4, 7]. However, our data shows that late PF was 
significant in the placebo arms in all RCTs (21.6%), 
and a more extended treatment schedule with cor-
ticosteroids may be necessary to find a significant 
difference for this endpoint. The RCT conducted 
by Yousef et al. randomized 120 patients to receive 
a 24-h infusion of methylprednisone (5 mg/kg) or 
placebo (normal saline infusion) the day before the 
initiation of radiotherapy. Four (7%) patients in the 
intervention group and 12 (20%) patients in the pla-
cebo group had PF (p < 0.05). The dose of corticoste-
roids in their study was much higher than the doses 
used in the other two studies. If we convert the dose 
used by Youssef et al. 5 mg/kg would be equivalent 
to 65 mg/day for a 70 kg patient. This brutal differ-
ence in corticosteroids dosage between Youssef et al. 
and other trials had a direct impact on the rate and 
duration of PF. The mean duration of PF in Youssef 
et al. was 125 days in the intervention group and 
375 days in the placebo group. Combining the three 
trials, the mean of PF days was significant but with 
heterogeneity. When Youssef trial was excluded, the 
result remained significant and with no heterogene-
ity, which validates the outcomes. Another question 
arising from our data regards the sample size of 
the studies. The studies may be considered under-
powered to detect the estimated difference from the 
statistical assumptions. For instance, Chow et al. 
[14] postulated a difference in the incidence of 17% 
between the arms. However, the group difference 
was 8.9% in the intention-to-treat, and the inci-
dence of late PF was practically the same between 
placebo and dexamethasone (9.4% and 10%) [14]. 
Thus, even increasing the sample size, it is improb-
able to imagine a significant difference between the 
arms. Our meta-analysis clarifies this point, with 
data from 611 patients randomized with a difference 
of 3% between the treatment arms and no statistical 
significance was detected. The absence of the benefit 
in the corticosteroids arm of reducing late PF reveals 
the necessity of changing the treatment strategy. For 
us, the way to do that would be to increase the corti-
coid dose or increase administration time to reduce 
the occurrence of late PF significantly. One example 
of this strategy is the corticosteroids administration 
to avoid cranial hypertension during brain metasta-
ses radiotherapy course. Brain metastases typically 
are treated with the administration of 16 mg/day of 
dexamethasone during 10 fractions of whole-brain 
radiotherapy without clinical severe adverse effects. 
Based on this experience, the changing of cortico-
steroids dose or intake time should not pose a sig-
nificant challenge.
Pain progression was another endpoint evaluated 
in our meta-analysis, and no significant difference 
between intervention and placebo was observed. 
RT effectively reduces the pain of BM independent-
ly of the histological subtype and the radiotherapy 
schedule employed [3]. Although corticosteroids 
have co-analgesic properties, the effectiveness of RT 
in reducing pain is so significant that the addiction 
of corticosteroids provides no benefit for this out-
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come. On the other hand, the combination effective-
ly maintained a high proportion of patients without 
PF and no pain progression than the placebo.
Although our study is a meta-analysis of RCTs, 
it has some limitations. The evaluation of some 
aspects with a possible relationship with PF oc-
currence in a meta-regression analysis was not ex-
plored, such as tumor histology, RT fractionation, 
bone location, and pain score baseline. We also did 
not evaluate the adverse effects of corticosteroids 
administration. However, in all the published RCTs 
the adverse effects had no significant differences 
between the study arms, which demotivated us to 
analyze this endpoint, and also none of the RCTs 
performed a subgroup analysis of these possible 
prognostic factors to provide information for per-
forming a metaregression.
conclusion
Prophylactic corticosteroids reduce significant-
ly the occurrence of early PF in bone metastases 
treated with radiotherapy. It also reduces the mean 
of days with PF and maintains a significant patient 
rate with no PF and no pain progression. However, 
the corticosteroids did not affect the incidence of 
late PF. Although it has co-analgesic properties, its 
use combined with RT did not produce any differ-
ence in the pain progression rate compared with 
the placebo. Consequently, its use should be strictly 
recommended to reduce early PF and shorten the 
days with PF in bone metastases treated with RT. 
Our findings call attention for a change in the strat-
egy to prevent PF in future randomized clinical 
trials, which should consider increasing the corti-
costeroids dose or the time of intake, establishing 
the late PF rate as the primary endpoint.
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